|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2008-9-26
|
|
pubmed:abstractText |
The CA 19-9 decline 8 weeks after gemcitabine administration has been shown to be a useful prognosticator of survival in patients with pancreatic cancer. We assessed the prognostic value of changes in CA 19-9 levels 4 weeks after treatment initiation on overall survival (OS) and time to progression (TTP).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
pubmed-author:ArizumiToshihikoT,
pubmed-author:HiranoKenjiK,
pubmed-author:IsayamaHiroyukiH,
pubmed-author:ItoYukikoY,
pubmed-author:KawabeTakaoT,
pubmed-author:KogureHirofumiH,
pubmed-author:MatsubaraSaburoS,
pubmed-author:NakaiYousukeY,
pubmed-author:OmataMasaoM,
pubmed-author:SasahiraNaokiN,
pubmed-author:SasakiTakashiT,
pubmed-author:TadaMinoruM,
pubmed-author:TogawaOsamuO,
pubmed-author:TsujinoTakeshiT,
pubmed-author:YagiokaHiroshiH,
pubmed-author:YashimaYokoY
|
|
pubmed:copyrightInfo |
Copyright 2008 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
75
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
120-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18784438-Adult,
pubmed-meshheading:18784438-Aged,
pubmed-meshheading:18784438-Aged, 80 and over,
pubmed-meshheading:18784438-Antimetabolites, Antineoplastic,
pubmed-meshheading:18784438-CA-19-9 Antigen,
pubmed-meshheading:18784438-Deoxycytidine,
pubmed-meshheading:18784438-Disease Progression,
pubmed-meshheading:18784438-Female,
pubmed-meshheading:18784438-Humans,
pubmed-meshheading:18784438-Male,
pubmed-meshheading:18784438-Middle Aged,
pubmed-meshheading:18784438-Pancreatic Neoplasms,
pubmed-meshheading:18784438-Prognosis,
pubmed-meshheading:18784438-Survival Analysis,
pubmed-meshheading:18784438-Treatment Outcome,
pubmed-meshheading:18784438-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
|
|
pubmed:affiliation |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article
|
